Abstract
Background:Rosuvastatin, a strong statin, and colestimide, a new anion exchange resin, are both clinically beneficial drugs for treatment of hypercholesterolemia. The main purpose of the study was to compare the effects of rosuvastatin and colestimide on metabolic parameters, adipokines, and markers of oxidative stress and diabetic nephropathy in patients with type 2 diabetes complicated by hyperlipidemia.Design:A total of 40 patients with type 2 diabetes complicated by hyperlipidemia were recruited prospectively and consecutively. The patients were assigned randomly in equal numbers to rosuvastatin (2.5 mg/day) and colestimide (3.0 g/day) groups. Blood and urine tests were performed at the beginning of the study and after 12 weeks.Results:Rosuvastatin significantly decreased the level of serum retinol-binding protein (RBP)-4, an insulin-resistant adipokine, in a subgroup of patients with poor glycemic control, in addition to exerting a strong low-density lipoprotein (LDL-C)-lowering effect. Colestimide significantly decreased HbA1c, even in patients treated with a sulfonylurea at a more than moderate dose, without influencing insulin resistance or adiponectin (an insulin-sensitive adipokine) and RBP4. Colestimide also significantly decreased the levels of urinary 8-iso-prostaglandin (PG) F2&agr; (a marker of oxidative stress) and urinary monocyte chemoattractant protein-1 (MCP-1) (a marker of diabetic nephropathy).Conclusion:Our results show that rosuvastatin and colestimide exert different beneficial effects in type 2 diabetic patients complicated by hyperlipidemia. Therefore, concomitant use of these drugs may be useful for prevention of progression of diabetic complications.
This content is limited to qualifying members.
If you have an existing account please login now to access this article or view purchase options.
Create a free account, then purchase this article to download or access it online for 24 hours.
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
References
References1. Colhoun HM, Betteridge DJ, Durrington PN, et al; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized trial and cohort study. Lancet 2004;364:685–696.ColhounHM]]BetteridgeDJ]]DurringtonPN&etal;CARDS investigatorsPrimary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized trial and cohort study.Lancet2004364685-6962. Cheng JW. Rosuvastatin in the management of hyperlipidemia. Clin Ther 2004;26:1368–1387.ChengJWRosuvastatin in the management of hyperlipidemia.Clin Ther2004261368-13873. Nissen SE, Nicholls SJ, Sipahi I, et al; ASTEROID Investigators. Effect of very high-insensitivity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006;295:1556–1565.NissenSE]]NichollsSJ]]SipahiI&etal;ASTEROID InvestigatorsEffect of very high-insensitivity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.JAMA20062951556-15654. Ortego M, Bustos C, Hernández-Presa MA, et al. Atorvastatin reduces NF&kgr;B activation and chemokine expression in vascular smooth muscle cells. Atherosclerosis 1999;147:253–261.OrtegoM]]BustosC]]Hernández-PresaMA&etal;Atorvastatin reduces NF&kgr;B activation and chemokine expression in vascular smooth muscle cells.Atherosclerosis1999147253-2615. Jialal I, Stein D, Balis D, Grundy SM, et al. Effect of hydroxymethyl glutaryl coenxyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001;103:1933–1935.JialalI]]SteinD]]BalisD]]GrundySM&etal;Effect of hydroxymethyl glutaryl coenxyme a reductase inhibitor therapy on high sensitive C-reactive protein levels.Circulation20011031933-19356. Hussein O, Schlezinger S, Rosenblat M, et al. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis 1997;128:11–18.HusseinO]]SchlezingerS]]RosenblatM&etal;Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL.Atherosclerosis199712811-187. Ramasubbu K, Estep J, White DL, et al. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 2008;51:415–426.RamasubbuK]]EstepJ]]WhiteDL&etal;Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy.J Am Coll Cardiol200851415-4268. Sugiyama S, Fukushima H, Kugiyama K, et al. Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis 2007;194:e43–e51.SugiyamaS]]FukushimaH]]KugiyamaK&etal;Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease.Atherosclerosis2007194e43-e519. Takagi T, Matsuda M, Abe M, et al. Effect of pravastatin on the development of diabetes and adiponectin production. Atherosclerosis 2008;196:114–121.TakagiT]]MatsudaM]]AbeM&etal;Effect of pravastatin on the development of diabetes and adiponectin production.Atherosclerosis2008196114-12110. Chu CH, Lee JK, Lam HC, et al. Atorvastatin does not affect insulin sensitivity and the adiponectin or leptin levels in hyperlipidemic type 2 diabetes. J Endocrinol Invest 2008;31:42–47.ChuCH]]LeeJK]]LamHC&etal;Atorvastatin does not affect insulin sensitivity and the adiponectin or leptin levels in hyperlipidemic type 2 diabetes.J Endocrinol Invest20083142-4711. Shetty GK, Economides PA, Horton ES, et al. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004;27:2450–2457.ShettyGK]]EconomidesPA]]HortonES&etal;Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes.Diabetes Care2004272450-245712. MCI-196 Study Group. Study on the usefulness of MCI-196 in patients with hypercholesterolemia. Rinsho Iyaku 1996;12:1641–1692.MCI-196 Study GroupStudy on the usefulness of MCI-196 in patients with hypercholesterolemia.Rinsho Iyaku1996121641-169213. Yamakawa T, Takano T, Utsunomiya H, et al. Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. Endocr J 2007;54:53–58.YamakawaT]]TakanoT]]UtsunomiyaH&etal;Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia.Endocr J20075453-5814. Kawabata Y, Ikegami H, Fujisawa T, et al. Bile acid binding resin ameliorates glycemic control in patients with type 2 diabetes [abstract]. Diabetes 2006;55(suppl 1):A120.KawabataY]]IkegamiH]]FujisawaT&etal;Bile acid binding resin ameliorates glycemic control in patients with type 2 diabetes [abstract].Diabetes200655A12015. Suzuki T, Oba K, Futami S, et al. Blood glucose-lowering activity of colestimide in patients with type 2 diabetes and hypercholesterolemia: a case-control study comparing colestimide with acarbose. J Nippon Med Sch 2006;73:277–284.SuzukiT]]ObaK]]FutamiS&etal;Blood glucose-lowering activity of colestimide in patients with type 2 diabetes and hypercholesterolemia: a case-control study comparing colestimide with acarbose.J Nippon Med Sch200673277-28416. Kobayashi M, Ikegami H, Fujisawa T, et al. Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes 2007;56:239–247.KobayashiM]]IkegamiH]]FujisawaT&etal;Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin.Diabetes200756239-24717. Yang Q, Graham TE, Mody N, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005;436:356–362.YangQ]]GrahamTE]]ModyN&etal;Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes.Nature2005436356-36218. Graham TE, Yang Q, Blüher M, et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006;354:2552–2563.GrahamTE]]YangQ]]BlüherM&etal;Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects.N Engl J Med20063542552-256319. Qi Q, Yu Z, Ye X, et al. Elevated retinol-binding protein 4 levels are associated with metabolic syndrome in Chinese people. J Clin Endocrinol Metab 2007;92:4827–4834.QiQ]]YuZ]]YeX&etal;Elevated retinol-binding protein 4 levels are associated with metabolic syndrome in Chinese people.J Clin Endocrinol Metab2007924827-483420. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidative stress in arterothrombotic disease. Arterioscler Thromb Vasc Biol 1997;17:2309–2315.PatronoC]]FitzGeraldGAIsoprostanes: potential markers of oxidative stress in arterothrombotic disease.Arterioscler Thromb Vasc Biol1997172309-231521. Reilly MP, Praticò D, Delanty N, et al. Increased formation of distinct F2&agr; isoprostanes in hypercholesterolemia. Circulation 1998;98:2822–2828.ReillyMP]]PraticòD]]DelantyN&etal;Increased formation of distinct F2&agr; isoprostanes in hypercholesterolemia.Circulation1998982822-282822. Wada T, Fruichi K, Sakai N, et al. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int 2000;58:1492–1499.WadaT]]FruichiK]]SakaiN&etal;Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy.Kidney Int2000581492-149923. Tesch GH. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol 2008;294:F697–F701.TeschGHMCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy.Am J Physiol Renal Physiol2008294F697-F70124. Helmersson J, Basu S. F2-isoprostane excretion rate and diurnal variation in human urine. Prostaglandins Leukot Essent Fatty Acids 1999;61:203–205.HelmerssonJ]]BasuSF2-isoprostane excretion rate and diurnal variation in human urine.Prostaglandins Leukot Essent Fatty Acids199961203-20525. Takebayashi K, Matsumoto S, Aso Y, et al. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J Clin Endocrinol Metab 2006;91:2214–2217.TakebayashiK]]MatsumotoS]]AsoY&etal;Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy.J Clin Endocrinol Metab2006912214-221726. Japan Diabetes Society. Treatment Guide for Diabetes. Tokyo, Japan, Bunkodo, 2007.Japan Diabetes SocietyTreatment Guide for Diabetes.Tokyo, JapanBunkodo200727. Panagiotakos DB, Pitsavos C, Skoumas J, et al. Importance of LDL/HDL cholesterol ratio as a predictor for coronary heart disease events in patients with heterozygous familial hypercholesterolaemia: a 15-year follow-up (1987–2002). Curr Med Res Opin 2003;19:89–94.PanagiotakosDB]]PitsavosC]]SkoumasJ&etal;Importance of LDL/HDL cholesterol ratio as a predictor for coronary heart disease events in patients with heterozygous familial hypercholesterolaemia: a 15-year follow-up (1987–2002).Curr Med Res Opin20031989-9428. Takebayashi K, Aso Y, Inukai T. Role of retinol-binding protein 4 in the pathogenesis of type 2 diabetes. Expert Rev Endocrinol Metab 2008;3:175–185.TakebayashiK]]AsoY]]InukaiTRole of retinol-binding protein 4 in the pathogenesis of type 2 diabetes.Expert Rev Endocrinol Metab20083175-18529. Takebayashi K, Suetsugu M, Wakabayashi S, et al. Retinol binding protein-4 levels and clinical features of type 2 diabetes patients. J Clin Endocrinol Metab 2007;92:2712–2719.TakebayashiK]]SuetsuguM]]WakabayashiS&etal;Retinol binding protein-4 levels and clinical features of type 2 diabetes patients.J Clin Endocrinol Metab2007922712-271930. Corna D, Sangalli F, Cattaneo D, et al. Effect of rosuvastatin on glomerular capillary size-selectivity function in rats with renal mass ablation. Am J Nephrol 2007;27:630–638.CornaD]]SangalliF]]CattaneoD&etal;Effect of rosuvastatin on glomerular capillary size-selectivity function in rats with renal mass ablation.Am J Nephrol200727630-63831. Onishi T, Sano N, Takikawa H. Effect of colestimide on absorption of unconjugated bile acids in the rat jejunum. J Gastroenterol Hepatol 2002;17:697–701.OnishiT]]SanoN]]TakikawaHEffect of colestimide on absorption of unconjugated bile acids in the rat jejunum.J Gastroenterol Hepatol200217697-70132. Kajiyama G, Tzazuma S, Yamashita G. Effect of MCI-196 on biliary lipids metabolism in patients with hypercholesterolemia. Rinsho Iyaku 1996;12:1349–1359.KajiyamaG]]TzazumaS]]YamashitaGEffect of MCI-196 on biliary lipids metabolism in patients with hypercholesterolemia.Rinsho Iyaku1996121349-135933. Ma K, Saha PK, Chan L, et al. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 2006;116:1102–1109.MaK]]SahaPK]]ChanL&etal;Farnesoid X receptor is essential for normal glucose homeostasis.J Clin Invest20061161102-110934. Watanabe M, Houten SM, Mataki C, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006;439:484–489.WatanabeM]]HoutenSM]]MatakiC&etal;Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation.Nature2006439484-48935. Jiang T, Wang XX, Scherzer P, et al. Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy. Diabetes 2007;56:2485–2493.JiangT]]WangXX]]ScherzerP&etal;Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy.Diabetes2007562485-2493
